| Ytd | -22.94% | |
| 1y | -20.27% |
| Open | 1.40 | Prev Close | 1.39 | Low | 1.37 | High | 1.45 | Mkt Cap | 258.36M |
| Vol | 100.71K | Avg Vol | 1.89M | EPS | -1.23 | P/E | N/A | Forward P/E | -1.01 |
| Beta | 2.75 | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.61 | 200-d Avg | 2.10 | 1yr Est | 11.77 |
NMRA News
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the ana
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concer
Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeut
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform
US stock futures rise, Nasdaq 100 up 1%. Datadog (DDOG) downgraded, pre-market trading. Other declin
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform a
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the
HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts work
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow
Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeut
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.30) per share which beat the ana
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations
Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and main
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the a
William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-51
William Blair analyst Myles Minter upgrades Neumora Therapeutics (NASDAQ:NMRA) from Market Perfor
Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) wi
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationK
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningfu
NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favor
Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeu
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningfu
RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perfor
Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises t
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the a
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and raises the
Guggenheim analyst Yatin Suneja upgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Buy a
Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neur
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like
